No Data
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March
Morgan Stanley Assumes Blueprint Medicines at Equal-Weight, Lowers Price Target of $100
Morgan Stanley Initiates Blueprint Medicines(BPMC.US) With Hold Rating, Announces Target Price $100
Balanced Outlook on Blueprint Medicines: Growth Prospects and Market Dynamics
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
